The following observational clinical trials are currently open for enrollment, though the individual requirements and treatments for each study differ.
Acute HIV Longitudinal Trial
The purpose of this observational study is to provide long-term follow up of acutely/recently HIV infected patients.
Requirements for this study include:
- Subjects with a negative antibody test three months prior to HIV+ test result
Treatment will include:
- Observation only; no medicine will be provided during study
To become involved, contact Kara McGee:
CHAVI 001 - Acute Observation Study
Chavi 001 is an acute HIV-1 infection prospective cohort study to acquire data for HIV vaccine development.
Requirements for this study include:
- Acutely diagnosed
- Control cohort HIV+/HIV-
Treatment will include:
To become involved, contact Kara McGee:
CHAVI 012 - Acute, Chronic, Uninfected
Acute infection observation study. One visit with possible follow-up.
Requirements for this study include:
- Acutely diagnosed within six months
- May be treatment naïve or on treatment
Possible procedures compensated by study:
- Colonoscopy with biopsy
- Bone marrow aspirate
- Leukopheresis
To become involved, contact Kara McGee:
CHAVI 008
The Chavi B-cell study intends to assess the immune systems of chronically infected patients to inform development of an HIV vaccine.
Requirements for this study include:
- Any CD4 count
- On or off ARVs
Treatment will include:
- Observational study; one time blood draw
To become involved, contact Kara McGee:
Fatty Acid Study
Comparison of fatty acid profile before and three months after initiation of ritonavir.
Requirements for this study include:
- Must be new to, or have been off ritonavir for >3 months
Treatment will include:
To become involved, contact Debbie McMullen:
Proteinuria
The purpose of this observational study is to assess endothelial cell function in HIV infected patients with and without proteinuria.
Requirements for this study include:
- HIV+
- HIV RNA of less than 50
- Age 18-50
Treatment will include:
To become involved, contact Joan Riddle, RN:
True Prevalance
Use of current or new genotype testing to detect low level resistance, particularly to NNRTIs that may cause treatment failure or emergence of further resistance.
Requirements for this study include:
- Naïve subjects about to initiate NNRTI and NRTI ART (no PI)
- Baseline genotype shows no NRTI or NNRTI resistance
- Viral load >25,000 copies
This is an observational study.
To become involved, contact Brian Lane:
